Please activate JavaScript!
Please install Adobe Flash Player, click here for download


75. Turelli P., Mangeat B., Jost S., Vianin S., Trono D., 2004. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303:1829. 76. Watters J.W., Kraja A., Meucci M.A., Province M.A., McLeod H.L., 2004. Genome- wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl. Acad. Sci. U. S. A 101:11809–11814. 77. Williams L.M., Cloyd M.W., 1991. Polymorphic human gene(s) determines diffe- rential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates. Virology 184:723–728. 78. Winkler C., An P., O’Brien S.J., 2004. Patterns of ethnic diversity among the genes that influence AIDS. Hum. Mol. Genet. 13 Spec No 1:R9–19. 79. Yan H., Yuan W., Velculescu V.E., Vogelstein B., Kinzler K.W., 2002. Allelic varia- tion in human gene expression. Science 297:1143. 80. Yerly S., Jost S., Telenti A., Flepp M., Kaiser L., Chave J.P., Vernazza P., Battegay M., Furrer H., Chanzy B., Burgisser P., Rickenbach M., Gebhardt M., Bernard M.C., Perneger T., Hirschel B., Perrin L., 2004. Infrequent transmission of HIV-1 drug- resistant variants. Antivir. Ther. 9:375–384. 81. Yuste E., Sanchez-Palomino S., Casado C., Domingo E., Lopez-Galindez C., 1999. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol 73:2745–2751. 82. Zhang J., Webb D.M., 2004. Rapid evolution of primate antiviral enzyme APO- BEC3G. Hum. Mol. Genet. 13:1785–1791. 83. ZhangY.-M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., Salzman N.P., 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 71:662–6670. 32